LPDNCT07009119

Laparoscopic Pancreaticoduodenectomy

StatusRecruiting

PhaseNot applicable

SponsorMinia University

Primary completionFeb 1, 2027 (estimated)

At risk: Primary completion moved 8 months later.

See at-risk trials from Minia University

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 4 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

Notable Nov 8, 2026 Primary completion pushed from Jun 1, 2026 to Feb 1, 2027
- Eligibility criteria expanded, about 16 words
- Study completion pushed from Jul 1, 2026 to Mar 1, 2027
Notable Aug 22, 2025 Primary endpoints: 3 to 1v4
Notable Jun 6, 2025 Trial status: Not Yet Recruiting to Recruiting
- Site details revised
v2
Jun 5, 2025 Study First Submitted

Notable: the plan changed

Endpoints

Primary

Pathological Assessment of Surgical Specimens

Timeframe: Assessed at the time of surgical specimen pathological evaluation (typically within 1-2 weeks post-surgery).

Secondary (6)

The rate of pancreatic fistula after pancreaticoduodenectomy

Operative time in minutes

Intra-operative blood loss

Postoperative length of stay

Amount of intraoperative blood transfusion

Show 1 moreShow less

Length of postoperative surgical intensive care unit stay

Arms and interventions

Laparoscopic pancreaticoduodenectomyOther

Laparoscopic pancreaticoduodenectomy: 1. dissection 2. reconstruction

Procedures: laparoscopic Pancreaticoduodenectomy

Sites

1 site in 1 country

Liver and GIT hospital , Minia UniversityMinya, Egypt

About this trial

Laparoscopic pancreaticoduodenectomy was first performed by Garner and Pomp in 1994. This is a technically difficult, time consuming and high rate of complication procedure. The reason is that duodenum and head of pancreas locate deeply in retroperitoneum and are surrounded by important structures such as inferior vena cava, abdominal aorta, superior mesenteric artery, superior mesenteric vein (SMV), portal vein (PV) and hepatic arteries. Injuring these structures during the surgery can lead to life-threatening complications. Moreover, doing anastomoses through laparoscopy, especially pancreatic anastomosis, is more difficult and takes more time than through open approach. The outcome of PD has improved over the last two decades due to advances in surgical techniques, anesthesia and perioperative care. Although studies from high volume centers demonstrate reduce in the operative mortality to less than 3%, the postoperative morbidity rate is still ranging from 30% to 60%. Laparoscopic surgery is being used increasingly as a less invasive alternative to traditional interventions for pancreatic resection. Laparoscopic pancreaticoduodenectomy (LPD) is a difficult procedure that has become increasingly popular. Nevertheless, comparative data on outcomes remain limited. In this prospective study, investigators evaluate the safety and feasibility of surgical and oncological outcomes of minimally invasive PD.

Trial details

Enrollment: 30 participants (estimated)
Started: Jun 1, 2025
Study completion: Mar 1, 2027 (estimated)
Eligibility: 18 to 75, all sexes, no healthy volunteers
Design: Interventional, open label, treatment
Oversight: Data monitoring committee
Conditions: Pancreatic Fistula, Pancreatic Neoplasms, Pancreatic Cancer, Periampullary Cancer
Official title: Feasibility, Safety and Short-term Oncosurgical Outcome of Laparoscopic Pancreaticoduodenectomy for Malignancy: A Single Centre Experience
First posted: Jun 6, 2025
Registry updated: Nov 12, 2026
Last verified: Nov 2026

Related trials at risk

View on ClinicalTrials.gov ↗